This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.
J-Pac and Doyen Medipharm together bring a unique combination of services to the medical device and pharmaceutical industries. As a contract manufacturer, J-Pac produces a wide range of advanced medical products ranging from implantable surgical products and orthopedic devices to diagnostic and oral thin films. J-Pac is investing in a number of areas including pharmaceutical products and is expanding its manufacturing footprint, including in Asia. Through its Doyen Division, the Company provides precision high-volume production equipment to medical device and biopharmaceutical companies for a number of applications including: wound care, advanced converting and packaging solutions and oral strip production with more than 200 machines in place worldwide.
Joseph E. Parzick, Managing Partner of Torque Capital, commented “We were attracted to J-Pac and Doyen because they enjoy strong brand recognition in the field of medical manufacturing and produce high quality products for a wide range of customers, large and small. We believe there is tremendous growth potential in high-value added outsourced manufacturing for the medical market as healthcare spending continues to increase worldwide due in part to the demands of an aging population. As we continue to add resources and capabilities, J-Pac and Doyen Medipharm are well positioned to become the go-to provider in the medical field.”
“We are very excited to join forces with Torque Capital” said Richard Eagling, CEO of
J-Pac and Doyen Medipharm. “The prospects for the future expansion of the company are greatly enhanced as we benefit from new investment and access to the wide-ranging manufacturing expertise and market access of the Torque operating resources.”
Joseph E. Parzick, Managing Partner of Torque Capital, commented “We were attracted to J-Pac and Doyen because they enjoy strong brand recognition in the field of medical manufacturing and produce high quality products for a wide range of customers, large and small. We believe there is tremendous growth potential in high-value added outsourced manufacturing for the medical market as healthcare spending continues to increase worldwide due in part to the demands of an aging population. As we continue to add resources and capabilities, J-Pac and Doyen Medipharm are well positioned to become the go-to provider in the medical field.”
“We are very excited to join forces with Torque Capital” said Richard Eagling, CEO of
J-Pac and Doyen Medipharm. “The prospects for the future expansion of the company are greatly enhanced as we benefit from new investment and access to the wide-ranging manufacturing expertise and market access of the Torque operating resources.”
Companies in this article
